Background and objective: The encouraging results of clinical trials for triple-negative breast cancer (TNBC) patients in recent years have gradually formed a system for the therapeutic regimen. As immunotherapy and precision therapy based on biomarkers have brought a new era to TNBC, it has become more crucial for clinicians to update the recommended treatment regimens for advanced TNBC patients.
Methods: We searched literatures related to the treatment for advanced TNBC from 2014 to 2022 on PubMed and sorted out them. In addition, the 2021-2022 guidelines in the part of treatment for advanced TNBC were downloaded on the official website of the guidelines referred to, which were summarized meanwhile.
Key content and findings: We summarized the current status of treatment for advanced TNBC from four aspects: immunotherapy, targeted therapy, antibody-drug conjugates (ADC) drug therapy and chemotherapy. The recommended therapeutic principles for the aspect of advanced TNBC in 2022 Chinese Society of Clinical Oncology (CSCO) guidelines were proposed in combination with international guidelines and conference recommendations.
Conclusions: It was emphasized that the detection and evaluation of biomarkers or targeting molecules should be the basis for choosing therapeutic regimens in this review and clinicians are supposed to accurately screen the population to achieve better treatment outcomes and prognosis for patients with advanced TNBC.
Keywords: Advanced triple-negative breast cancer (advanced TNBC); antibody-drug conjugates (ADC) drug therapy; biomarkers; immunotherapy; targeted therapy.
2022 Translational Breast Cancer Research. All rights reserved.